Global IP Protection: U.S. “Priority Watch List” Includes Major Suppliers
Executive Summary
The U.S. Trade Representative's 2009 Special 301 Report cites a number of countries that serve as major suppliers of pharmaceuticals for failing to provide adequate protection of intellectual property rights
You may also be interested in...
Global IP Protection: Data Exclusivity Is Top USTR Concern As Licensing Recedes
The U.S. Trade Representative's most recent report on global intellectual property rights suggests compulsory licensing may be receding somewhat as a worry for pharmaceutical companies, but inadequate data protection remains a strong concern
Global IP Protection: Data Exclusivity Is Top USTR Concern As Licensing Recedes
The U.S. Trade Representative's most recent report on global intellectual property rights suggests compulsory licensing may be receding somewhat as a worry for pharmaceutical companies, but inadequate data protection remains a strong concern
Intellectual Property Protection: Foreign Governments Get To Argue Their Case To USTR Before Publication Of "Watch Lists"
For the first time, the U.S. Trade Representative is giving foreign governments and others a chance to publicly testify before issuing its 2010 Special 301 report on countries it deems do not provide adequate protection of intellectual property rights